The role focuses on improving an AI model that identifies patients likely to have transthyretin (ATTR) cardiac amyloidosis through clinical chart review, patient case labeling, and evidence-based clinical reasoning.

• Engagement: Part-time with a commitment of approximately 10–20 hours per week.
• Required role: US-based clinicians only.
• Focus: Patient chart annotation, clinical reasoning, and AI model improvement.

Contract and Payment Terms

• You will be engaged as an independent contractor.
• This is a fully remote role that can be completed on your own schedule.
• Projects can be extended, shortened, or concluded early depending on needs and performance.
• Your work at Mercor will not involve access to confidential or proprietary information from any employer, client, or institution.
• Payments are weekly on Stripe or Wise based on services rendered.
• Please note: We are unable to support H1-B or STEM OPT candidates at this time.

• Review patient charts and assess the likelihood of ATTR cardiac amyloidosis, including cases with incomplete information.
• Identify relevant clinical signals, including patient history and diagnostic findings such as PYP scans, where applicable.
• Document clear, evidence-based reasoning; distinguish ATTR from similar conditions and maintain consistent labeling standards.
• Refine assessments based on new evidence and AI model feedback, explain clinical decisions to technical teams, and meet labeling deadlines.

Work arrangement: Fully remote

Eligible countries: United States